Gensight Biologics SA (SIGHT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gensight Biologics SA (SIGHT) has a cash flow conversion efficiency ratio of 0.083x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.68 Million ≈ $-3.13 Million USD) by net assets (€-32.11 Million ≈ $-37.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gensight Biologics SA - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Gensight Biologics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SIGHT liabilities breakdown for a breakdown of total debt and financial obligations.
Gensight Biologics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gensight Biologics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crescent NV
BR:OPTI
|
0.172x |
|
GP Petroleums Limited
NSE:GULFPETRO
|
0.039x |
|
Amj Land Holdings Limited
NSE:AMJLAND
|
0.037x |
|
ZOONO Group Ltd
AU:ZNO
|
-0.356x |
|
Flexion Mobile PLC
ST:FLEXM
|
0.022x |
|
Sporting Clube de Braga - Futebol SAD
LS:SCB
|
-0.342x |
|
Celsius Resources Ltd
AU:CLA
|
-0.046x |
|
Ihlas Yayin Holding A.S.
IS:IHYAY
|
0.011x |
Annual Cash Flow Conversion Efficiency for Gensight Biologics SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Gensight Biologics SA from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Gensight Biologics SA (SIGHT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-26.92 Million ≈ $-31.47 Million |
€-12.94 Million ≈ $-15.12 Million |
0.481x | -40.18% |
| 2023-12-31 | €-30.70 Million ≈ $-35.89 Million |
€-24.66 Million ≈ $-28.83 Million |
0.803x | -63.64% |
| 2022-12-31 | €-15.28 Million ≈ $-17.86 Million |
€-33.75 Million ≈ $-39.46 Million |
2.209x | +306.10% |
| 2021-12-31 | €15.99 Million ≈ $18.69 Million |
€-17.14 Million ≈ $-20.04 Million |
-1.072x | +16.87% |
| 2020-12-31 | €11.67 Million ≈ $13.64 Million |
€-15.04 Million ≈ $-17.59 Million |
-1.289x | +46.12% |
| 2019-12-31 | €11.75 Million ≈ $13.73 Million |
€-28.11 Million ≈ $-32.87 Million |
-2.393x | -101.28% |
| 2018-12-31 | €23.87 Million ≈ $27.91 Million |
€-28.38 Million ≈ $-33.18 Million |
-1.189x | -248.17% |
| 2017-12-31 | €55.00 Million ≈ $64.30 Million |
€-18.78 Million ≈ $-21.96 Million |
-0.342x | +7.26% |
| 2016-12-31 | €53.34 Million ≈ $62.36 Million |
€-19.64 Million ≈ $-22.96 Million |
-0.368x | +10.71% |
| 2015-12-31 | €29.33 Million ≈ $34.29 Million |
€-12.09 Million ≈ $-14.14 Million |
-0.412x | +20.91% |
| 2014-12-31 | €10.58 Million ≈ $12.37 Million |
€-5.52 Million ≈ $-6.45 Million |
-0.521x | -353.65% |
| 2013-12-31 | €16.97 Million ≈ $19.83 Million |
€-1.95 Million ≈ $-2.28 Million |
-0.115x | -- |
About Gensight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more